Evidence of safety for pretomanid and male reproductive health

Affiliations

¹ The Prince Charles Hospital, Brisbane, QLD, Australia, Faculty of Medicine, The University of Queensland School of Medicine, Herston, QLD, Australia.
² Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, Sydney Institute for Infectious Diseases, University of Sydney, Sydney, NSW, Australia.
³ Victorian Tuberculosis Program, Melbourne Health, Melbourne, VIC, Australia, Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.

Editorial

A Burke et al. Int J Tuberc Lung Dis. 2022.

. 2022 Jun 1;26(6):473-474.

doi: 10.5588/ijtld.22.0092.

¹ The Prince Charles Hospital, Brisbane, QLD, Australia, Faculty of Medicine, The University of Queensland School of Medicine, Herston, QLD, Australia.
² Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, Sydney Institute for Infectious Diseases, University of Sydney, Sydney, NSW, Australia.
³ Victorian Tuberculosis Program, Melbourne Health, Melbourne, VIC, Australia, Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.

No abstract available

Comment on

Male reproductive hormones in patients treated with pretomanid.
Boekelheide K, Olugbosi M, Nedelman J, Everitt D, Smith E, Betteridge M, Sun E, Spigelman M. Boekelheide K, et al. Int J Tuberc Lung Dis. 2022 Jun 1;26(6):558-565. doi: 10.5588/ijtld.21.0654. Int J Tuberc Lung Dis. 2022. PMID: 35650700 Free PMC article.